公开(公告)号：WO2006056779A3

公开(公告)日：2007-07-05

申请号：PCT/GB2005004511

申请日：2005-11-24

Applicant: UCB PHARMA SA ,  BROWN DEREK THOMAS ,  KIRBY HISHANI ,  FINNEY HELENE MARGARET ,  LAWSON ALASTAIR DAVID GRIFFITH

Inventor： BROWN DEREK THOMAS ,  KIRBY HISHANI ,  FINNEY HELENE MARGARET ,  LAWSON ALASTAIR DAVID GRIFFITH

IPC: C07K16/24 ,  A61K39/395 ,  A61P37/06

CPC classification number: C07K16/241 ,  C07K2317/56 ,  C07K2317/76

Abstract: Anti-TNFa antibodies which selectively inhibit TNFa signalling through the p55R. In particular anti-TNFa antibodies which selectively inhibit TNFa signalling through the p55R relative to the p75R.

Abstract translation: 通过p55R选择性抑制TNFa信号传导的抗TNFα抗体。 特别是抗TNFa抗体，其通过p55R相对于p75R选择性地抑制TNFa信号转导。

公开(公告)号：UA118954C2

公开(公告)日：2019-04-10

申请号：UAA201413210

申请日：2013-05-13

Applicant: UCB PHARMA SA

Inventor： FINNEY HELENE MARGARET ,  LAWSON ALASTAIR DAVID GRIFFITHS ,  SHAW STEVAN GRAHAM ,  SMITH BRYAN JOHM ,  TYSON KERRY LOUISE ,  KEVORKIAN LARA ,  MEIER CHRISTOPH ,  SARKAR KAUSHIK ,  ATHERFOLD PAUL ALAN

IPC: C07K16/28 ,  A61K39/395 ,  A61P17/00 ,  C07K14/00 ,  G01N33/531

Abstract: Винахідстосуєтьсяанти-FcRn антитіла, абойогозв'язуючогофрагмента, аналізудлятестуванняздатностізазначеногоантитілаблокуватиактивність FcRn людини, виділеноїпослідовностіДНК, вектораклонуванняабоекспресії, клітини-хазяїна, способуотриманнятакогоантитіла, фармацевтичноїкомпозиції, способулікуванняпацієнтавідаутоімуннихзахворювань, опосередкованих FcRn.

公开(公告)号：AP201408102A0

公开(公告)日：2014-12-31

申请号：AP201408102

申请日：2013-05-13

Applicant: UCB PHARMA SA

Inventor： SARKAR KAUSHIK ,  ATHERFOLD PAUL ALAN ,  FINNEY HELENE MARGARET

IPC: C07K16/28 ,  G01N33/53

公开(公告)号：CA2778673A1

公开(公告)日：2011-05-05

申请号：CA2778673

申请日：2010-10-27

Applicant: UCB PHARMA SA

Inventor： MILLER KAREN MARGRETE ,  DE RYCK MARC ROGER ,  WOLFF CHRISTIAN GILBERT J ,  LAWSON ALASTAIR DAVID GRIFFITHS ,  FINNEY HELENE MARGARET ,  BAKER TERENCE SEWARD

IPC: C07K16/28

Abstract: A Nav1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti- Nav1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

公开(公告)号：CA2778671C

公开(公告)日：2019-02-19

申请号：CA2778671

申请日：2010-10-27

Applicant: UCB PHARMA SA

Inventor： MILLER KAREN MARGRETE ,  DE RYCK MARC ROGER ,  WOLFF CHRISTIAN GILBERT J ,  LAWSON ALASTAIR DAVID GRIFFITHS ,  FINNEY HELENE MARGARET ,  BAKER TERENCE SEWARD

IPC: C07K16/28

Abstract: An anti- E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

公开(公告)号：PE20150002A1

公开(公告)日：2015-01-28

申请号：PE2014001987

申请日：2013-05-13

Applicant: UCB PHARMA SA

Inventor： FINNEY HELENE MARGARET ,  LAWSON ALASTAIR DAVID GRIFFITHS ,  SHAW STEVAN GRAHAM ,  SMITH BRYAN JOHN ,  TYSON KERRY LOUISE ,  KEVORKIAN LARA ,  MEIER CHRISTOPH ,  SARKAR KAUSHIK ,  ATHERFOLD PAUL ALAN

IPC: G01N33/53 ,  C07K16/28

Abstract: SE REFIERE A UN ANTICUERPO O FRAGMENTO DE UNION DEL MISMO ANTI-FCRN QUE COMPRENDE: UNA CADENA PESADA QUE TIENE UNA REGION VARIABLE QUE COMPRENDE TRES CDR SELECCIONADAS INDEPENDIENTEMENTE DE SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 ; Y UNA CADENA LIGERA QUE TIENE UNA REGION VARIABLE QUE COMPRENDE TRES CDR SELECCIONADAS INDEPENDIENTEMENTE DE SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNES.

公开(公告)号：AU2013298924A1

公开(公告)日：2015-01-15

申请号：AU2013298924

申请日：2013-05-13

Applicant: UCB PHARMA SA

Inventor： FINNEY HELENE MARGARET ,  LAWSON ALASTAIR DAVID GRIFFITHS ,  SHAW STEVAN GRAHAM ,  SMITH BRYAN JOHN ,  TYSON KERRY LOUISE ,  KEVORKIAN LARA ,  MEIER CHRISTOPH ,  SARKAR KAUSHIK ,  ATHERFOLD PAUL ALAN

IPC: C07K16/28 ,  G01N33/53

Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

公开(公告)号：AP2014008102A0

公开(公告)日：2014-12-31

申请号：AP2014008102

申请日：2013-05-13

Applicant: UCB PHARMA SA

Inventor： SARKAR KAUSHIK ,  ATHERFOLD PAUL ALAN ,  FINNEY HELENE MARGARET

IPC: C07K16/28 ,  G01N33/53

Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

公开(公告)号：CA2872326A1

公开(公告)日：2014-02-06

申请号：CA2872326

申请日：2013-05-13

Applicant: UCB PHARMA SA

Inventor： FINNEY HELENE MARGARET ,  LAWSON ALASTAIR DAVID GRIFFITHS ,  SHAW STEVAN GRAHAM ,  SMITH BRYAN JOHN ,  TYSON KERRY LOUISE ,  KEVORKIAN LARA ,  MEIER CHRISTOPH ,  SARKAR KAUSHIK ,  ATHERFOLD PAUL ALAN

IPC: C07K16/28 ,  G01N33/53

Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.

公开(公告)号：AU2003278354A1

公开(公告)日：2004-05-25

申请号：AU2003278354

申请日：2003-10-28

Applicant: UCB PHARMA SA

Inventor： FINNEY HELENE MARGARET ,  LAWSON ALASTAIR DAVID GRIFFITH

IPC: C07K14/705 ,  C07K16/28 ,  C12N15/62 ,  A61K38/17 ,  C12N5/10

Abstract: Nucleic acids are described which code for chimeric cytoplasmic signalling molecules containing at least one cytoplasmic signalling sequence derived from CD134 or ICOS. The nucleic acids may be expressed in cells to produce chimeric receptors and other proteins which are able to regulate cell activation processes. Such regulated cells are of use in medicine, for example in the treatment of infectious, inflammatory and autoimmune diseases.